Abstract
We evaluated the activity of ceftibuten combinations with avibactam, ledaborbactam, and xeruborbactam against isogenic Escherichia coli and clinical Enterobacterales isolates producing broad-spectrum β-lactamases. Avibactam and ledaborbactam enhanced ceftibuten activity against transformants producing serine-β-lactamases. Ceftibuten/xeruborbactam was also active against VIM and some IMP producers. All combinations were active against OXA-48- and KPC-producing clinical isolates. Ceftibuten/xeruborbactam also retained activity against VIM-producing clinical strains. Susceptibility rates for MBL producers varied, depending on the CLSI or EUCAST breakpoints applied.
Funding Information
  • Instituto de Salud Carlos III (CB21/13/00055)
  • Instituto de Salud Carlos III (PI25/00116)
  • Axencia Galega de Innovación (IN606A 2024/022)
  • Axencia Galega de Innovación (IN606A 2025/020)
  • Axencia Galega de Innovación (IN607A 2024/09)
  • Axencia Galega de Innovación (IN607D 2021/12)
  • Axencia Galega de Innovación (IN607D 2024/08)
  • Instituto de Salud Carlos III (CM23/00095)
  • Instituto de Salud Carlos III (CM23/00104)
  • Instituto de Salud Carlos III (FI23/00074)
  • Instituto de Salud Carlos III (JR21/00026)
  • Instituto de Salud Carlos III (PI21/00704)
  • Instituto de Salud Carlos III (PI22/01212)
  • Instituto de Salud Carlos III (PI23/00851)
  • Instituto de Salud Carlos III (PI24/00920)

This publication has 29 references indexed in Scilit: